FOLLOW-UP OF THE 1985-86 NHLBI PTCA REGISTRY

NHLBI经皮腔内注射是一致同意的 冠状动脉血管成形术(PTCA)注册调查人员，他们是 先驱和最有资格的侵入性心脏病专家，那10年 对一九八五至八六年度的2433名病人进行跟进是当务之急。 临床和血管造影特征以及手术细节 患者和病变水平都经过了仔细的测量和记录 在这群人中。颈椎的临床状态和解剖变化的资料 每年或每次重复程序时都会更新尸检结果 已执行。1985-86年的PTCA是通过至今仍在进行的技术进行的 电流。自那以后，人们对其进行了改进，但这些都只是 对成功率和并发症发生率的影响最小。有症状的和 解剖学上的疾病特征与那些 今天正在接受PTCA。出于这些原因，延长了后续信息 将与20世纪90年代的治疗决策相关。一个主要的动机 对于延长的随访，是从搭桥手术中吸取的教训 记录了治疗失败率增加的研究 术后5~7年开始疗效。 拥有10年的经验，并致力于PTCA我们的评估 协调中心在与以下机构的合作中有着良好的记录 16个注册临床站点。随访率保持在95%以上。 科学报告定期分发给公众，并受到公众的欢迎 心内科社区。为了与其他经皮穿刺术保持同步 冠状动脉介入治疗的选择，我们最近建立了一个新的注册 设备。在拟议的后续行动结束时，两家公司的调查人员 登记处将能够整合所学到的知识。 目前，预计新设备不会取代 PTCA在经皮冠状动脉血运重建中的应用。此外，结果显示， 将补充那些将在5年内提供的服务 在冠状动脉旁路成形术中接受PTCA或CABG治疗的患者 血运重建调查。 到目前为止，书记官处已经确定，在PTCA后4年， 扩张成功的患者死亡率为6%。三十五岁 需要重复血运重建的百分比，其中11%需要搭桥 做手术。超过75%的患者在PTCA术后四年内没有症状 不管最初的成功与否。

There is unanimous agreement among the NHLBI Percutaneous Transiluminal Coronary Angioplasty (PTCA) Registry investigators, who are among the pioneers and the best qualified invasive cardiologists, that 10-year follow-up of the 2433 patients in the 1985-86 cohort is imperative. Clinical and angiographic characteristics as well as procedural details on both patient and lesion levels have been carefully measured and documented in this cohort. Data on the clinical status and anatomical changes in the coronaries have been updated annually or whenever repeat procedures were performed. PTCA in 1985-86 was carried out by techniques that are still current. Since then refinements have been made, but these have had only minimal effect on success and complication rates. Symptomatic and anatomical disease characteristics are similar to those of patients who are undergoing PTCA today. For these reasons extended follow-up information will be relevant to therapeutic decisions in the 1990s. A major motivation for the extended follow-up is the lesson learned from bypass surgery studies that documented an increased frequency of loss of therapeutic efficacy beginning 5-7 years after the operation. With 10-years experience and dedication to the evaluation of PTCA our Coordinating Center has an excellent track record in collaboration with the 16 Registry clinical sites. Over 95% follow-up rate has been maintained. Scientific reports are regularly disseminated to, and well received by, the cardiology community. In order to keep abreast with other percutaneous coronary intervention options, we recently established a Registry of new devices. By the end of the proposed follow-up, investigators of both Registries will be in the position to integrate what was learned. Currently, it is not expected that new devices will replace the role of PTCA in percutaneous coronary revascularization. Furthermore, the results will complement those which will become available in the 5-year follow-up of patients treated with PTCA or CABG in the Bypass Angioplasty Revascularization Investigation. Thus far the Registry has established that 4 years after PTCA, the mortality rate was 6% for successfully dilated patients. Thirty-five percent required repeat revascularization of which 11% was with bypass surgery. Over 75% of patients were asymptomatic four years after PTCA regardless of initial success.